Swedish Orphan Biovitrum AB (publ) (LON:0MTD)

Market Cap	7.97B
Revenue (ttm)	1.88B
Net Income (ttm)	280.39M
Shares Out	n/a
EPS (ttm)	0.81
PE Ratio	28.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,642
Average Volume	141,040
Open	316.80
Previous Close	313.86
Day's Range	310.66 - 317.20
52-Week Range	17.57 - 25.61
Beta	0.26
RSI	38.11
Earnings Date	Feb 5, 2025

About LON:0MTD

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,840
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MTD

Financial Performance

In 2024, LON:0MTD's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK